Theoretically, they operate through different mechanisms: semaglutide suppresses appetite and slows gastric emptying via GLP-1 receptors, while AOD 9604 acts on beta-3 adrenergic receptors on fat cells
It can be used alongside caloric restriction without exacerbating hunger, combined with exercise programs without compromising fueling needs, or integrated with behavioral nutrition approaches that rely on intact hunger and satiety signaling for long-term habit formation
They can change the dose or how often you get shots based on your progress
Through its selective action on adipose tissue and beta-3 adrenergic receptors, this peptide stimulates lipolysis and fat oxidation without triggering the appetite changes, glucose disruptions, or hormonal alterations commonly associated with weight loss interventions
Common side effects and what they mean Most people who use AOD 9604 experience either no side effects or very mild, transient effects that resolve without intervention
They usually last 30 minutes to an hour
